Chronic Post-leptospirosis Manifestations in Reunion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

198 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-25

Study Completion Date

2026-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Leptospirosis is a zoonosis caused by spirochetes, pathogenic bacteria of the genus Leptospira. It is transmitted to humans through mucocutaneous lesions by contact with water or soil contaminated by the urine of animal reservoirs (rats, dogs, pigs, cattle, etc.). Exposure to fresh water, contact with water or soil contaminated with animal waste are the main risk factors.

This disease is an important public health problem in humans and animals. The annual global incidence is estimated at nearly one million cases with a mortality of 5 to 10% for all cases combined and up to 50% in the event of multi-organ failure. The number of cases is growing and the disease is probably more widespread because it is underdiagnosed. The incidence could increase further in the coming decades due to climate change and rapid urbanization.

In the Overseas Departments and Regions (DROM), it is an endemic condition and its incidence is 10 to 100 times higher than that of mainland France, mainly for climatic reasons. In Réunion, the disease is notifiable with a number of notified cases ranging from 70 to more than 100 cases per year in recent years. Nearly 90% of confirmed cases were hospitalized and more than a third of patients stayed in intensive care.

Recently, a multicenter cohort of patients hospitalized with leptospirosis in La Réunion (COLEPT) was funded by Inserm to identify the severity factors of the disease in patients hospitalized in one of the 4 hospitals on the island. A community of hospital practitioners active on this theme has been identified and constitutes the core of this project. The main objective of the study, the inclusions of which began in January 2020, is to identify the severity factors of leptospirosis in Reunion. Patient follow-up is planned for up to 1 year with 2 medical visits at 1 month and 1 year and 2 telephone interviews on quality of life.

The disease is generally perceived as a purely acute condition with a rapid ad integrum recovery. Nevertheless, the evolution at a distance has been little evaluated. A few publications report complications and elements of chronicity in the medium/long term (\>1 year) which would require monitoring these patients over a longer period. Regarding these potential chronic manifestations, they may be chronic fatigue, uveitis, renal failure, chronic renal carriage with urinary excretion of leptospires, myalgia and muscle weakness, headaches, malaise but also cardiac or neurological manifestations. A Dutch study conducted on subjects with confirmed diagnosis reported 30% of patients with chronic post-leptospirosis symptoms which persisted in 21% of subjects more than 24 months after infection, but very few data are available on the chronic forms.

The objective will be to study the future of patients beyond 1 year of infection in clinical and serological terms, but also in terms of quality of life, use of alternative medicines and complementary and health literacy profiles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Seroprevalence of Leptospirosis in Val Müstair, Switzerland

NCT05300425

Leptospirosis Hepatitis E Virus Infection Tularemia

COMPLETED

Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?

NCT02612896

Taenia Solium Infection

COMPLETED NA

Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections.

NCT04505046

Testing Performance Specificity +1 more

UNKNOWN

Diagnostic of Puumala Virus Infection in France

NCT02455375

Nephropathia Epidemica Hemorrhagic Fever With Renal Syndrome

COMPLETED

Assessment and Treatment of Loiasis With Positive Microfilaremia

NCT06194149

Loiasis With Positive Blood Microfilaremia

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leptospirosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sampling and clinical data collection

* Biological sampling and collection:

* whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)
* urine: 1 bottle of 30ml
* Freezing of serum after centrifugation
* Storage at Biological Ressources Center
* Collection of clinico-biological data on a dedicated eCRF

Group Type OTHER

Biological sampling and collection

Intervention Type OTHER

* Biological sampling and collection:

* whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)
* urine: 1 bottle of 30ml
* Freezing of serum after centrifugation
* Storage
* Collection of clinico-biological data on a dedicated eCRF

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological sampling and collection

* Biological sampling and collection:

* whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)
* urine: 1 bottle of 30ml
* Freezing of serum after centrifugation
* Storage
* Collection of clinico-biological data on a dedicated eCRF

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult or child subjects having been included in the COLEPT cohort with confirmed leptospirosis Where
* Adult subjects or children hospitalized for leptospirosis confirmed within 12-18 months before LEPTONIC inclusion;
* Be resident in Reunion
* Ability to answer a telephone questionnaire
* Benefit from a social security scheme

Exclusion Criteria

* Refusal of participation by the patient or his entourage if the patient is physically unable to give his opinion (coma, resuscitation, etc.).
* Exclusion or premature termination of participation in the COLEPT cohort
* Patient under judicial safeguard, guardianship or curatorship, under activated future protection mandate and family authorization

Eligible Sex

ALL

Accepts Healthy Volunteers

No